🇺🇸 FDA
Pipeline program

HGT-1111

HGT-MLD-049

Phase 2 small_molecule terminated

Quick answer

HGT-1111 for Late Infantile Metachromatic Leukodystrophy is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Late Infantile Metachromatic Leukodystrophy
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials